Changing the Way Anti-Cancer Drugs Are Developed
Cell Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel agents that improve the safety and efficacy of existing standard-of-care cancer treatments, and those with unique, new mechanisms to kill cancer cells. We use genomic information to determine which tumors have the greatest chance of responding favorably to a specific drug candidate. This technology has the potential to change the way anti-cancer drugs are developed, by allowing investigators to pick the right drug for the right patient. It also has the potential to increase efficacy, lower development costs and approval time, and aim our best science at the highest-value markets.
Building Momentum
We have one product on the market and three product candidates in late-stage clinical development, as well as clinical and preclinical product candidates that may address the therapeutic limitations of conventional cancer therapies. Our capabilities span drug discovery, development, and commercialization.
 |
Corporate Profile
Investment Highlights
Novel oncology portfolio spanning the entire spectrum of drug discovery, development, and commercialization
Novel technology base to generate substantial licensing revenue streams
Strong proprietary position through patents and orphan drug designation
Proven merger and acquisition strategy
Key Statistics
Ownership: Public
Ticker Symbol: CTIC
Initial Public Offering: March 1997
Exchanges: NASDAQ, AMEX, PSEX, CBOE, MTA
Collaborations: Novartis, PG-TXL Company, L.P., Nerviano Medical Sciences, Translational Genomics Research Institute
The information provided on this site may contain Forward Looking Statements. For complete text of this statement, refer to Terms of Use. |
|
